Member access

4-Traders Homepage  >  Shares  >  Swiss Exchange  >  Actelion Ltd    ATLN   CH0010532478

ACTELION LTD (ATLN)

55
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Actelion Ltd
Develops, produces and markets pharmaceutical drugs

Actelion Ltd. operates as a holding company with interests in developing, producing and marketing pharmaceutical drugs.

It is a biopharmaceutical company, which focuses on the drug discovery, development, registration, production and commercialization of innovative drugs for diseases with significant unmet medical needs.

The company's portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications.

It has treatments for specialist diseases, including Type 1 Gaucher disease, Niemann-Pick type C disease, digital ulcers in patients suffering from systemic sclerosis and mycosis fungoides in patients with cutaneous T-cell lymphoma.

The company products include Tracleer (bosentan), Zavesca (miglustat), Ventavis (iloprost), Veletri (epoprostenol for injection), Valchlor and Opsumit (macitentan).

Actelion was founded by Jean-Paul Clozel, Martine Clozel, Walter Fischli, André J. Mueller, and Thomas Widmann on December 17, 1997 and is headquartered in Allschwil, Switzerland.
Sales per Businesses
20132014Delta
CHF (in Million)%CHF (in Million)%
Drugs1,786100%1,958100% +8.79%
Sales per Regions
20132014Delta
CHF (in Million)%CHF (in Million)%
United States767.9643%879.2444.9% +12.66%
Europe632.0635.4%687.8235.1% +8.11%
Other356.6620%360.5218.4% +1.07%
Switzerland29.061.6%30.301.5% +4.12%
Managers
NameAgeSinceTitle
Jean-Paul Clozel601997Chief Executive Officer & Executive Director
Jean-Pierre Garnier682011Chairman
Otto Schwarz602008Chief Operating Officer & Executive Vice President
André C. Muller, MBA522013Chief Financial Officer & Executive Vice President
Martine Clozel, MD601997Chief Scientific Officer & Senior Vice President
Guy Braunstein MD, PhD592009Executive VP & Head-Global Clinical Development
Michael Jacobi, PhD622009Non-Executive Director
Werner Henrich72-Non-Executive Director
Jean Pierre Malo CFA, MBA61-Non-Executive Director
Juhani Anttila61-Non-Executive Director
Shareholders
NameShares%
BlackRock Investment Management (UK) Ltd. 6,169,763 5.41%
Rudolf Maag, MBA 6,067,305 5.32%
Jean-Paul Clozel, MD 5,281,544 4.63%
Orbis Investment Management Ltd. 3,568,489 3.13%
Actelion Ltd. 3,457,446 3.03%
Fidelity Management & Research Co. 3,169,472 2.78%
Wellington Management Co. LLP 2,479,895 2.17%
Artisan Partners LP 2,388,350 2.09%
Bellevue Asset Management AG 2,307,513 2.02%
Norges Bank Investment Management 2,025,137 1.77%
Holdings
NameShares%Valuation
Actelion Ltd (ATLN) 3,457,4463.03%400,811,723 USD
Sector
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Bio Therapeutic Drugs
Advertisement
Sector Biotechnology & Medical Research
Growth (Revenue) Profitability
ACTELION LTD
SHANGHAI RAAS BLO..
-
MEDIVATION INC
INTERCEPT PHARMAC..
RECEPTOS INC
JUNO THERAPEUTICS..
-
HUALAN BIOLOGICAL..
GENMAB A/S
BLUEBIRD BIO INC
TONGHUA DONGBAO P..
BEIJING SL PHARMA..
DYAX CORP.
AGIOS PHARMACEUTI..
NEUROCRINE BIOSCI..
AUSPEX PHARMACEUT..
-
CLOVIS ONCOLOGY I..
KITE PHARMA INC
TESARO INC
CHINA BIOLOGIC PR..
ULTRAGENYX PHARMA..
-
Sector Biotechnology & Medical Research
Actelion Ltd : Connections
CFA Institute
Cerenis Therapeutics, Inc.
Newman's Own Foundation
Urrma AG
Avalon Advisors LLC
Max Planck Institute For Biophysical Chemistry
Immuno International AG
TET Systems AG
Martin Hilti Family Trust
PharmaSens AG
Hilti AG
Society of Financial Analysts of Houston
ArgYou AG
ValCrea AG
Actelion Pharmaceuticals UK Ltd.
Pivalor AG
Anttila & Co. Advisors
Company contact information
16 Gewerbestrasse
CH-4123 Allschwil, Basel-Landschaft
Switzerland

Phone : +41 61 565 65 65
Fax : +41 61 565 65 00
Internet : http://www.actelion.com
Markets and indexes
- SIX Swiss Exchange
- Main Standard
- SMI /
Stock Exchange Codes
- ISIN Code :  CH0010532478
- Bloomberg Code :  ATLN:VX
- Reuters Code :  ATLN.VX
- Datastream Code :  S:ATLN
© 2015 People , Fundamentals and Ownership    © 2015 Cofisem   
Dynamic quotes  
ON
| OFF